The influence of displacement compounds on the binding of ochratoxin A to human serum albumin examined with fluorescence anisotropy methods

• Autorzy: Wybranowski T , Ziomkowska B. , Cwynar A , Kruszewski S.

Identyfikatory

DOI

10.5277/oa140301

• Języki publikacji: EN

Abstrakty

EN

The subject of the research is the application of the methods of fluorescence anisotropy measurements to study the interaction between human serum albumin (HSA) and toxins and selected medicines (ibuprofen, warfarin, flurbiprofen). Optical spectroscopic methods are useful tools for the study of biologically active compounds. Determining binding intensity of ochratoxin A (OTA) to albumin may be helpful in explaining the effects of toxic influence of OTA. The main factor influencing the distribution of OTA is its affinity for plasma proteins. It was shown that ochratoxin binds strongly to albumin. By the use of the method of fluorescence anisotropy it was proved that the unbound fraction of OTA is higher due to competing interactions with drugs. As a result of separating ochratoxin from protein by competitive compounds, a decrease in the fluorescence anisotropy of the HSA-OTA complex was observed. The largest increase in free fraction of OTA is caused by flurbiprofen, then ibuprofen and warfarin. It will accelerate OTA transport to target organs and shortening its half-life period, leading consequently to a decrease in chronic toxic effects.

Słowa kluczowe

EN

ochratoxin A; binding of drug to albumin; flurbiprofen; ibuprofen; warfarin

• Wydawca: Oficyna Wydawnicza Politechniki Wrocławskiej
• Czasopismo: Optica Applicata
• Rocznik: 2014
• Tom: Vol. 44, nr 3
• Strony: 357--364
• Opis fizyczny: Bibliogr. 16 poz., tab., wykr.

Twórcy

autor

Wybranowski T

• Medical Physics Division, Biophysics Department, Collegium Medicum of Nicolaus Copernicus University, Jagiellońska 13, 85-067 Bydgoszcz, Poland

autor

Ziomkowska B.

• Medical Physics Division, Biophysics Department, Collegium Medicum of Nicolaus Copernicus University, Jagiellońska 13, 85-067 Bydgoszcz, Poland

autor

Cwynar A

• Laboratory of Cell Biology and Genetics, Collegium Medicum of Nicolaus Copernicus University, Jagiellońska 13, 85-067 Bydgoszcz, Poland

autor

Kruszewski S.

• Medical Physics Division, Biophysics Department, Collegium Medicum of Nicolaus Copernicus University, Jagiellońska 13, 85-067 Bydgoszcz, Poland

Bibliografia

• [1] KRUSZEWSKI S., SIUDA R., ZIOMKOWSKA B., CYRANKIEWICZ M., Application of principal component and factor analysis of fluorescence spectra in camptothecin studies, Optica Applicata 33(2–3), 2003, pp. 369–380.
• [2] WYBRANOWSKI T., CYRANKIEWICZ M., ZIOMKOWSKA B., KRUSZEWSKI S., The HSA affinity of warfarin and flurbiprofen determined by fluorescence anisotropy measurements of camptothecin, Biosystems 94(3), 2008, pp. 258–262.
• [3] DASGUPTA A., Handbook of Drug Monitoring Methods: Therapeutics and Drugs of Abuse, Human Press INC, Totowa, New Jersey, 2008.
• [4] COHEN L.H., Plasma protein-binding methods in drug discovery, [In] Optimization in Drug Discovery, Methods in Pharmacology and Toxicology, Zhengyin Yan, Caldwell G.W. [Eds.], Humana Press, 2004, pp. 111–122.
• [5] SJÖHOLM I., EKMAN B., KOBER A., LJUNGSTEDT-PÅHLMAN I., SEIVING B., SJÖDIN T., Binding of drugs to human serum albumin: XI. The specificity of three binding sites as studied with albumin immobilized in microparticles, Molecular Pharmacology 16(3), 1979, pp. 767–777.
• [6] SUDLOW G., BIRKETT D.J., WADE D.N., The characterization of two specific drug binding sites on human serum albumin, Molecular Pharmacology 11(6), 1975, pp. 824–832.
• [7] RAHMAN M.M., RAHMAN M.H., RAHMAN N.N., Competitive binding of ibuprofen and naproxen to bovine serum albumin: modified form of drug–drug displacement interaction at the binding site, Pakistan Journal of Pharmaceutical Sciences 18(1), 2005, pp. 43–47.
• [8] IL’ICHEV YU.V., PERRY. J.L., SIMON J.D., Interaction of ochratoxin A with human serum albumin. A common binding site of ochratoxin A and warfarin in subdomain IIA, The Journal of Physical Chemistry B 106(2), 2002, pp. 460–465.
• [9] PODLEWSKI J.K., CHWALIBOGOWSKA-PODLEWSKA A., Leki Współczesnej Terapii – Encyklopedia dla Farmaceuty, Split Trading, 2007, (in Polish).
• [10] LAKOWICZ J.R., Principles of Fluorescence Spectroscopy, Kluwer Academic, New York, 1999.
• [11] MISHRA B., BARIK A., PRIYADARSINI K.I., MOHAN H., Fluorescence spectroscopic studies on binding of a flavonoid antioxidant quercetin to serum albumins, Journal of Chemical Sciences 117(6), 2005, pp. 641–647.
• [12] RUTQVIST L., BJÖRKLUND N.E., HULT K., HÖKBY E., CARLSSON B., Ochratoxin A as the cause of spontaneous nephropathy in fattening pigs, Applied and Environmental Microbiology 36(6), 1978, pp. 920–925.
• [13] KROGH P., Ochratoxin A residues in tissues of slaughter pigs with nephropathy, Nordisk Veterinaer- -Medicin 29(9), 1977, pp. 402–405.
• [14] ELLING F., MØLLER T., Mycotoxic nephropathy in pigs, Bulletin of the World Health Organization 49(4), 1973, pp. 411-418.
• [15] PETZINGER E., ZIEGLER K., Ochratoxin A from a toxicological perspective, Journal of Veterinary Pharmacology and Therapeutics 23(2), 2000, pp. 91–98.
• [16] WYBRANOWSKI T., ZIOMKOWSKA B., KRUSZEWSKI S., Antioxidant properties of flavonoids and honeys studied by optical spectroscopy methods, Medical and Biological Sciences 27(4), 2013, pp. 53–58.